New guidance on post-transplant diabetes

iabetes after solid organ transplantation (SOT) may seem a very niche topic, but as transplantation is an established life-saving treatment for people with organ failure and survival rates are steadily improving, hyperglycaemia amongst people undergoing SOT is increasingly common. Studies suggest that around 10–40% of patients undergoing SOT develop post-transplant diabetes (PTDM; Byrne et al, 2018).

Notwithstanding the COVID-19 pandemic, transplantation rates are likely to grow, especially as the UK now has a "presumed consent" approach to organ donation (NHS Blood and Transplant, 2020). Furthermore, long-term follow-up of patients undergoing transplantation is increasingly managed in local district hospitals rather than in large transplant centres, and therefore many diabetes nurse specialists or primary care nurses may see patients with diabetes who have undergone organ transplantation. The new guidance from the Association of British Clinical Diabetologists and the Renal Association (Chowdhury et al, 2021) on prevention, detection and management of PTDM is, therefore, welcome. The guidance carries the caveat that many studies in the area are small, short-term and uncontrolled, and hence the evidence behind many of the interventions is really quite weak.

The guidance outlines the epidemiology, pathogenesis and prevention strategies for PTDM. However, the main core of the guide is the detection and management of this condition (Figure 1). For centres managing patients undergoing transplantation, the guidance is clear that PTDM should not be diagnosed within 3 months of transplantation. The reason for this is that high doses of steroids and immunosuppression, coupled with stress from the operation, infection, pain and other factors (such as enteral feeding), very frequently lead to transient hyperglycaemia, which may improve with time. Nevertheless, this immediate postoperative hyperglycaemia should be actively screened for and managed.

The optimum screening method for postoperative hyperglycaemia is the use of afternoon capillary blood glucose (CBG) measurements. This is because the use of steroids and immunosuppression (especially calcineurin inhibitors such as tacrolimus) often leads to postprandial hyperglycaemia, and such patients may quite frequently have normal fasting glucose levels. The guidelines suggest that if hyperglycaemia is significant and persistent (two CBG measurements >11 mmol/L), treatment should be initiated. If CBG values are 11.0-13.9 mmol/L, oral hypoglycaemic therapy with metformin (if renal function allows) or a sulfonylurea may be tried. If glucose readings are above 14 mmol/L on two occasions, however, insulin therapy is advocated, either intravenously using variable-rate insulin infusion (if oral intake is poor), or with once-daily NPH insulin given subcutaneously in the morning as a starting regimen. Patients will need input from the multidisciplinary diabetes team, including diabetes nurses and dietitians, to help improve lifestyle and learn insulin administration and glucose testing.

Most transplant patients are seen weekly following discharge, and glucose levels should be regularly reviewed. As immunosuppression doses are reduced, hyperglycaemia may improve and clinicians will need to proactively reduce therapy to avoid hypoglycaemia.

At 3 months postoperatively, most patients are on stable immunosuppression doses and, therefore, can be screened for PTDM using either an oral glucose tolerance test or, much more conveniently, with an HbA_{1c} test, using the standard criteria for diagnosis of diabetes advocated by the World Health Organization (fasting plasma glucose \geq 7.0 mmol/L, 2-hour glucose \geq 11.1 mmol/L or HbA_{1c} \geq 48 mmol/mol [6.5%]). If diabetes is confirmed, the transplant team should ensure the diagnosis is added to the patient's clinical record and their primary healthcare team is informed, so that structured diabetes education and regular screening and care can be provided.



Tahseen A Chowdhury Consultant in Diabetes, Royal London Hospital

Preoperative

- Establish risk factors for diabetes (obesity, family history, previous GDM, high-risk ethnic group, glucocorticoid therapy).
- Monitor FPG and HbA_{1c} ideally 6-monthly: High risk if FPG 6.1–6.9 mmol/L or HbA_{1c} 42–47 mmol/mol (6.1–6.4%).
- If high risk of diabetes, advise weight loss, increased exercise and improved diet, smoking cessation.
- If HbA_{1c} >48 mmol/mol or FPG >7.0 mmol/L on two occasions, diagnose diabetes and put on to standard diabetes pathway.

Immediately postoperative

- Monitor afternoon CBG readings.
- If CBG persistently (two readings) >11.0 mmol/L, consider therapy.
- If CBG 11.0–13.9 mmol/L and patient is eating and clinically well, consider oral hypoglycaemic therapy (metformin [if eGFR >30 mL/min/1.73 m²], DPP-4 inhibitor or sulfonylurea, alone or in combination, may be used).
- If CBG >14.0 mmol/L on two occasions, commence insulin therapy:
 - If clinically unstable and/or not eating, give VRIII with intravenous 5% glucose.
 - If clinically stable and eating, commence subcutaneous NPH insulin 10 units and rapidly titrate.
 - Consider adding metformin if no contraindications.
 - CBG target 4-12 mmol/L.
 - Refer for dietetic advice to reduce glycaemic excursions.
 - Refer for education regarding insulin therapy and CBG monitoring, and undergo regular follow-up by a healthcare professional with expertise in diabetes management.
 - Ensure primary care is aware of diagnosis of post-transplant hyperglycaemia.

Up to 6 weeks postoperative

- Regular review with aim to reduce glucocorticoid dose, stabilise immunosuppression and consider conversion to less diabetogenic CNI therapy (e.g. ciclosporin) if no signs of rejection and graft function is stable.
- Reduce oral hypoglycaemic therapy or insulin if possible.
- Ensure diet and lifestyle changes are optimised.
- At 6 weeks, consider OGTT if practical.
- During OGTT, if FPG >7.0 mmol/L or 2-hour glucose >11.1 mmol/L, diagnose PTDM and treat as below.

3 months postoperative

If CBG well controlled and HbA₁, at target, consider reduction in anti-hyperglycaemic therapy with careful self-monitoring of CBG.

- If hyperglycaemia resolved (CBG <11 mmol/L) and off anti-hyperglycaemic therapy, screen for PTDM with OGTT if possible; if not, request HbA_{1c} and FPG:
- If HbA_{1c} >48 mmol/mol (6.5%) or FPG >7.0 mmol/L on two occasions, diagnose PTDM.
 - Ensure patient and their primary healthcare team are informed of the diagnosis and the diagnosis is coded on the patient's electronic care record.
 - Refer patient for structured education and regular screening of eyes, feet, kidneys, blood pressure, weight, smoking status and lipids.
 - Manage cardiovascular risk factors.
 - Individualise glycaemic target according to patient's preference and comorbidities.
 - Drugs such as metformin (if eGFR >30 mL/min/1.73 m²), DPP-4 inhibitors, GLP-1 receptor agonists and insulin can all be used safely post-transplantation.
 - Avoid pioglitazone and saxagliptin in heart failure.
 - Seek specialist advice when considering SGLT2 inhibitors.
- If HbA_{1c} <42 mmol/mol (6.0%) and FPG <6.0 mmol/L, PTDM is not diagnosed and hyperglycaemia has resolved. Continue to monitor HbA_{1c} and FPG at 12 months and then annually.
- If HbA₁₂ 42–47 mmol/mol (6.0–6.4%) or FPG 6.1–6.9 mmol/L, patient is at risk of developing PTDM.
- Continue to monitor HbA₁, and FPG at 6-monthly intervals.
- Offer lifestyle advice to reduce risk of developing PTDM.

Figure 1. Pathway for diagnosis and management of post-transplant diabetes.

CBG=capillary blood glucose; CNI=calcineurin inhibitor; DPP-4=dipeptidyl peptidase-4; eGFR=estimated glomerular filtration rate; FPG=fasting plasma glucose; GDM=gestational diabetes; GLP-1=glucagon-like peptide-1; NPH=neutral protamine Hagedorn; OGTT=oral glucose tolerance test; PTDM=post-transplant diabetes; SGLT2=sodium–glucose cotransporter 2; VRIII=variable-rate intravenous insulin infusion.

If glucose management is difficult in a person who develops PTDM, consideration can be given to changing immunosuppression regimens to less diabetogenic ones, which may reduce hyperglycaemia, although this must be tempered with the increased risk of rejection. For example, tacrolimus appears to be much more diabetogenic than ciclosporin, although risk of rejection with the former is significantly lower (Sharif et al, 2011).

The guidance also outlines the importance of screening for diabetes in patients awaiting transplantation. This can be difficult using HbA_{1c} because anaemia (commonly seen in patients on dialysis) can falsely lower HbA_{1c}, so at least yearly fasting plasma glucose checks should be performed in patients awaiting transplantation. Finally, prevention of diabetes is discussed for this group. Improvements in diet and physical activity may have a role in reducing the risk of developing PTDM.

Overall, this guideline has reviewed all available

evidence and developed a coherent pathway in this important condition, which transplant and diabetes teams may find useful to follow. As the area is currently rather evidence-poor, the guideline also highlights areas required for further research and some possible audit standards, in the hope that areas lacking in evidence could start to be developed, and detection and management in this group of patients improves over time.

- Byrne C, Caskey F, Castledine C et al (2018) UK Renal Registry 20th Annual Report of the Renal Association. *Nephron* **139**(Suppl 1)
- Chowdhury TA, Wahba M, Mallik R et al (2021) Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. *Diabet Med* 12 Jan: e14523 [Epub ahead of print]. <u>https://doi.org/10.1111/dme.14523</u>
- NHS Blood and Transplant (2020) Organ donation law in the UK: The way organ donation works has changed. You still have a choice. NHS England, London. Available at: https://bit.ly/2ZtiGxm (accessed 18.02.21)
- Sharif A, Shabir S, Chand S et al (2011) Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. *J Am Soc Nephrol* **22**: 2107–18



The full guideline is available here.